Cargando…

ATR Inhibitors in Platinum-Resistant Ovarian Cancer

SIMPLE SUMMARY: Platinum-resistant ovarian cancer (PROC) is a deadly cancer with a poor prognosis. Some drugs targeting ATR have shown initial success in the treatment of PROC. Therefore, we reviewed the mechanism of the ATR pathway, the results of preclinical and clinical trials in PROC, and potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Siyu, Wang, Tao, Fei, Xichang, Zhang, Mingjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740197/ https://www.ncbi.nlm.nih.gov/pubmed/36497387 http://dx.doi.org/10.3390/cancers14235902

Ejemplares similares

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer
por: Nie, Sipei, et al.
Publicado: (2021)

A prognostic model based on the Augmin family genes for LGG patients
por: Wang, Tao, et al.
Publicado: (2023)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

Platinum resistance in breast and ovarian cancer cell lines
por: Eckstein, Niels
Publicado: (2011)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Prospects for the Use of ATR Inhibitors to Treat Cancer
por: Wagner, Jill M., et al.
Publicado: (2010)

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response
por: Bradbury, Alice, et al.
Publicado: (2022)

Emerging strategies for cancer therapy by ATR inhibitors
por: Yano, Kimiyoshi, et al.
Publicado: (2023)

Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives
por: Awada, Ahmad, et al.
Publicado: (2022)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023)

Aldehyde dehydrogenase inhibitors promote DNA damage in ovarian cancer and synergize with ATM/ATR inhibitors
por: Grimley, Edward, et al.
Publicado: (2021)

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2020)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
por: Leamon, Christopher P, et al.
Publicado: (2013)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers
por: Atallah, Ghofraan Abdulsalam, et al.
Publicado: (2023)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
por: Normann, Marius C., et al.
Publicado: (2019)

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
por: Agarwal, Amit, et al.
Publicado: (2021)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
por: Mantia-Smaldone, Gina M, et al.
Publicado: (2010)

Prediction of Key Candidate Genes for Platinum Resistance in Ovarian Cancer
por: Guo, Kaidi, et al.
Publicado: (2021)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Altered glutamine metabolism in platinum resistant ovarian cancer
por: Hudson, Chantelle D., et al.
Publicado: (2016)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer
por: Luyckx, Mathieu, et al.
Publicado: (2014)

Progress towards a clinically-successful ATR inhibitor for cancer therapy
por: Barnieh, Francis M., et al.
Publicado: (2021)

Mutation analysis of the ATR gene in breast and ovarian cancer families
por: Heikkinen, Katri, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_2btmh204orum1logu81fthtnkp